Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

(2014) Marcin Imielinski et al.   JOURNAL OF CLINICAL INVESTIGATION

Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling

(2013) Alyson K. Freeman et al.   MOLECULAR CELL

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

(2012) Maria Vinci et al.   BMC BIOLOGY

Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling

(2012) Michael Röring et al.   EMBO JOURNAL

Flotillin-1/Reggie-2 Protein Plays Dual Role in Activation of Receptor-tyrosine Kinase/Mitogen-activated Protein Kinase Signaling

(2012) Monia Amaddii et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers

(2012) A P Rebocho et al.   ONCOGENE

c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma

(2011) Rafael B. Blasco et al.   CANCER CELL

Single Substitution within the RKTR Motif Impairs Kinase Activity but Promotes Dimerization of RAF Kinase

(2011) Angela Baljuls et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting RAF: trials and tribulations

(2011) Julian Downward   NATURE MEDICINE

RAF protein-serine/threonine kinases: Structure and regulation

(2010) Robert Roskoski   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

(2010) Roque Diaz et al.   BMC CANCER

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Multicellular tumor spheroids: An underestimated tool is catching up again

(2010) Franziska Hirschhaeuser et al.   JOURNAL OF BIOTECHNOLOGY

Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth

(2010) Josette Carnahan et al.   MOLECULAR CANCER THERAPEUTICS

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

(2010) William Lee et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

(2009) Anurag Singh et al.   CANCER CELL

A dimerization-dependent mechanism drives RAF catalytic activation

(2009) Thanashan Rajakulendran et al.   NATURE

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

(2009) Bijay S. Jaiswal et al.   PLoS One

Positive Regulation of A-RAF by Phosphorylation of Isoform-specific Hinge Segment and Identification of Novel Phosphorylation Sites

(2008) Angela Baljuls et al.   JOURNAL OF BIOLOGICAL CHEMISTRY